Document:

EX-10.1

 Exhibit 10.1 
 JOINT DEFENSE PRIVILEGED SETTLEMENT AND RELEASE AGREEMENT 
 This
Settlement and Release Agreement (“Agreement”) is made and entered effective July 30, 2013 (the “Effective Date”), by and between SurModics, Inc. (“SurModics”) and Southern Research Institute (“SRI”).

 WHEREAS, SurModics, Inc., and SRI entered into a Stock Purchase Agreement on July 31, 2007, which includes certain
indemnification provisions; 
 WHEREAS, SRI, SurModics, and SurModics Pharmaceuticals, Inc. are defendants to an action pending
in the Circuit Court of Jefferson County, Alabama, entitled Richard M. Gilley and Herbert M. Blatter v. Southern Research Institute, et. al. (Case No. 09-901412) (the “Alabama Action”); 

WHEREAS, the parties are engaged in pending litigation in a case styled SurModics, Inc. v. Southern Research Institute in the
United States District Court for the District of Minnesota, Civil Action No. 11-01450 (the “Minnesota Action”) whereby (a) SurModics is seeking a judicial declaration regarding its rights to indemnification under the Stock
Purchase Agreement for certain Losses it has incurred, or will incur, in connection with the Alabama Action, and (b) SRI is seeking a judicial declaration regarding its rights to indemnification under the Stock Purchase Agreement for certain
Losses it has incurred, or will incur, in connection with the Alabama Action; and 
 WHEREAS, the parties hereto wish to settle
and discontinue the Minnesota Action and believe that doing so will inure to their common interest in defending the Alabama Action. 
 NOW, THEREFORE, in consideration of the mutual terms and conditions contained herein, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

 

	 	1.	Definitions. The capitalized terms set forth below, as used in this Agreement, shall have the following meanings. Capitalized terms that are not otherwise
defined herein shall have the meaning given to such terms in the Stock Purchase Agreement. 

  

	 	A.	“SurModics Releasees” shall mean SurModics and its past and present employees, partners, agents, predecessors, successors, assigns, heirs, executors,
administrators, officers, representatives, attorneys, agents, shareholders and directors. 

  

	 	B.	“SRI Releasees” shall mean SRI and its past and present employees, partners, agents, predecessors, successors, assigns, heirs, executors, administrators,
officers, representatives, attorneys, agents, shareholders and directors. 

	 	C.	“Past Unreimbursed Fees” shall mean all fees, costs, or expenses that the SurModics Indemnitees have incurred in connection with the Alabama Action through
June 30, 2013, as reflected on Exhibit A attached hereto. 

  

	 	D.	“Future Fees” shall mean all fees, costs, or expenses that the SurModics Indemnitees have incurred, or will incur, in connection with the Alabama Action that
are not reflected on Exhibit A, subject to SRI’s limited right of objection as set forth in paragraph 2(b). Future Fees shall not include the fees, costs, or expenses of any SurModics Expert Witnesses. 

 

	 	E.	“SurModics Expert Witnesses” shall mean any expert witness that has been, or that may be, engaged by SurModics in connection with the Alabama Action,
including without limitation, Grant Thornton LLP. 

  

	 	F.	“SurModics Indemnitees” shall have the meaning given to such term in Section 8.1 of the Stock Purchase Agreement. 

 

	 	2.	Agreement to Pay Past and Future Fees. SRI agrees that it will pay to SurModics seventy-five percent (75%) of (a) the Past Unreimbursed Fees, and
(b) the Future Fees as follows: 

  

	 	(a)	Payment of Past Unreimbursed Fees. SRI shall make the following payments to SurModics which, in the aggregate, constitute seventy-five percent (75%) of the
Past Unreimbursed Fees reflected on Exhibit A: 

  

	 	(i)	Within ten (10) business days from the Effective Date, SRI shall make a payment in the amount of Four Hundred Ninety-Two Thousand, Six Hundred Seventy-One Dollars
and Eighty-Five Cents ($492,671.85); and 

  

	 	(ii)	Within sixty (60) calendar days from the Effective Date, SRI shall make an additional payment in the amount of Four Hundred Ninety-Two Thousand, Six Hundred
Seventy-One Dollars and Eighty-Four Cents ($492,671.84). 

  

	 	(b)	 Payment of Future Fees. No later than fifteen (15) days after the end of each month after the Effective Date, SurModics will deliver to
SRI, for its review, a fee and expense schedule (each, a “Monthly Schedule”) setting forth, in reasonable detail, the Future Fees since the delivery of the prior Monthly Schedule (or, for the first Monthly Schedule after the Effective
Date, all Future Fees incurred prior to and since the Effective Date). Actual invoices (and any other supporting documentation) upon which a respective Monthly Schedule is based shall be provided along with the Monthly Schedule. SRI shall have the
ability to: (i) review SurModics’s invoices solely to ensure that the Future Fees are not excessive, and (ii) within thirty (30) calendar days from receiving each Monthly Schedule, object in writing to any fees or expenses in the
Monthly Schedule that SRI believes are 

  
 2 

	 	
excessive. Along with any written objection to the Future Fees, SRI will provide to SurModics a copy of SRI’s invoices reflecting fees, costs, or expenses incurred by SRI during the
same time period for purposes of resolving the objected-to Future Fees. For purposes of this provision, the word “excessive” shall mean fees or expenses that are a significant or material departure from what is reasonable under the
circumstances. SRI specifically agrees that: (x) the normal hourly rates of SurModics’s counsel are not “excessive” for purposes of this provision, and (y) SRI will not challenge those normal hourly rates provided those
rates do not increase beyond historical incremental increases in rates previously billed. If SRI fails to object in writing to any Monthly Schedule within such 30-day period, such Monthly Schedule shall be final and binding. Within thirty
(30) calendar days of receiving each Monthly Schedule and corresponding invoices, SRI shall pay to SurModics seventy-five percent (75%) of the Future Fees set forth on such Monthly Schedule less any portion thereof that SRI has objected to
as excessive. During the thirty (30) calendar days following delivery by SRI of any written objection to Future Fees (“Settlement Period”), SRI and SurModics shall use good faith efforts to resolve such objections and reach a written
agreement settling such objections. If the parties are unable to resolve such objections during the Settlement Period, then SurModics and SRI agree to resolve their dispute through the following process: 

 

	 	1.	SRI and SurModics agree to choose one mutually-acceptable former judge registered with JAMS, Inc. (the “Neutral”) to resolve the objections regarding Future
Fees (or, if the parties cannot agree upon a Neutral, they shall allow JAMS to select a Neutral from a list of 10 qualifying neutrals, a list from which each party will have the opportunity to strike up to 2 neutrals before JAMS makes its
selection). SRI and SurModics will jointly instruct the Neutral to resolve the dispute over objected-to Future Fees. 

  

	 	2.	SRI and SurModics may each provide the Neutral with a written summary of its position regarding the objected-to Future Fees, along with a copy of all relevant invoices
and any other supporting documents. The parties agree that they are not entitled to conduct any discovery (including interrogatories, document requests, requests for admission, or depositions) before submitting the materials to the Neutral. However,
SRI agrees that, in accordance with the written objection process set forth above, SurModics shall be entitled to receive a copy of invoices reflecting SRI’s fees, costs, or expenses during the relevant period of time. 

  
 3 

	 	3.	SRI and SurModics expressly agree that a decision by the Neutral as to the resolution of the objected-to Future Fees shall be conclusive and binding upon the parties
(unless the parties agree in writing that the Neutral has made a manifest error). The Neutral’s determination shall be (i) in writing; (ii) non-appealable by the parties and not subject to collateral attack for any reason; and
(iii) issued within 30 days of the parties’ filing with JAMS. 

  

	 	5.	The fees and costs of the Neutral shall be allocated between SurModics, on the one hand, and SRI, on the other hand, in inverse proportion to the extent they prevailed
on the items in dispute. The Neutral shall be responsible for so allocating its fees and costs as between SRI and SurModics and will include such allocation with the Neutral’s written determination. 

 

	 	(c)	Payment Method. Payments required under this paragraph 2 shall be made by wire transfer of immediately available funds to: 

 

					
		 	Bank Name:	  	Wells Fargo Bank N.A, San Francisco, CA
		 	Beneficiary Account Name:	  	SURMODICS INC
		 	Wire Routing Transit Number:	  	 XXXXXXX

		 	Beneficiary Account Number:	  	 XXXXXXX

		 	Swift Code:	  	 XXXXXXX

			
		 	Company:	  	 SurModics, Inc.
 9924 West 74th
Street
 Eden Prairie, MN 55344-3523

Andrew D. C. LaFrence
 Vice President, Finance
& CFO
 (952) 500-XXXX

  

	 	3.	Agreement Regarding Expert Witness and Other Fees. SurModics agrees that it shall be solely responsible for the fees, costs, or expenses of any SurModics Expert
Witnesses that have been, or that may be, incurred in connection with the Alabama Action. SurModics further agrees that it will not seek indemnification from SRI for SurModics’s past or future fees, costs, or expenses incurred in connection
with the Minnesota Action. SRI agrees that it shall be solely responsible for the fees, costs, or expenses of any expert witness that has been, or that may be, engaged by SRI in connection with the Alabama Action. SRI further agrees that it will not
seek indemnification from SurModics for SRI’s past or future fees, costs, or expenses incurred in connection with the Alabama Action or the Minnesota Action. 

  
 4 

	 	4.	Release of SRI Releasees. Effective upon the Effective Date, SurModics, on behalf of itself and the SurModics Indemnitees, hereby releases, acquits, exonerates
and forever discharges the SRI Releasees from any and all claims, demands, damages, actions, or suits, known and unknown, specifically related to SurModics’ claims under the SPA for indemnification for Past Unreimbursed Fees and Future Fees
except as expressly set forth herein, provided, however, that nothing in this paragraph 4 or this Agreement shall be interpreted to release SRI from its obligation to make payments in accordance with Paragraph 2. Provided SRI makes payments to
SurModics for Future Fees in accordance with paragraph 2(b) of this Agreement, SurModics agrees that it will not seek indemnification for or make other claims or demands for Future Fees. 

 

	 	5.	Release of SurModics Releasees. Effective upon the Effective Date, SRI, on behalf of itself and the SRI Releasees, hereby releases, acquits, exonerates and
forever discharges the SurModics Releasees from any and all claims, demands, damages, actions, or suits, known and unknown, specifically related to SRI’s claims for indemnification under the SPA for its fees, costs, or expenses that SRI has
incurred, or will incur, in connection with the Alabama Action. 

  

	 	6.	Scope of Agreement. This Agreement (including the releases contained herein) applies only to claims or demands under the SPA for indemnification of fees, costs,
or expenses that have been or will be incurred in connection with the Alabama Action and in no way relates to any claims for indemnification under the SPA for any substantive liability, judgment, or settlement in or related to the Alabama Action.
The parties understand and expressly acknowledge that they may later assert these excepted claims against one another for indemnification. 

  

	 	7.	Dismissal of Claims. For the consideration described herein, the parties agree that, within three (3) business days of the Effective Date, SRI will dismiss
its pending appeal of the Minnesota Action. 

  

	 	8.	Final Agreement. The parties hereto declare and represent that no promise, endorsement or agreement not herein expressed has been made to them and that this
Agreement contains the entire agreement between the parties related to fees, costs, and expenses incurred in the Alabama Action and that the terms of this Agreement are contractual and not mere recitals. 

 

	 	9.	No Reliance. The parties hereto are not relying and have not relied on any representation or statement by any other party hereto with respect to the facts
involved in this controversy, or with regard to their rights or asserted rights. 

  

	 	10.	Authority. The parties hereto further warrant and represent that no other person or entity has any interest in the matters released herein and that they have not
assigned, transferred or purported to assign or transfer to any person or entity all or any portion of the matters released. Each person executing this Agreement represents and warrants that he or she has authority to enter into this Agreement on
behalf of himself, herself or any indicated entity. 

  
 5 

	 	11.	Binding Effect. This Agreement shall inure to the benefit of the parties hereto and shall be binding upon each of them, and their heirs, estates, assigns,
representatives and successors. Except as expressly set forth in this Agreement, nothing herein is intended to amend, modify, terminate or constitute a waiver by either party with respect to any provision of the Stock Purchase Agreement, which
agreement shall remain in full force and effect. 

  

	 	12.	Confidentiality. The terms of this Agreement are confidential. The parties agree that they shall not divulge the terms of this Agreement to any person or entity
whatsoever at any time, except that such disclosure may be made: (a) by either party as required by law; (b) to the parties’ attorneys, tax, or financial advisors; or (c) by SurModics if in its reasonable judgment such disclosure
is required to be made in its filings with the United States Securities and Exchange Commission or any other regulatory body that may require disclosure. 

  

	 	13.	Joint Defense Privilege. This Agreement is part of an ongoing and joint effort between SurModics and SRI to set up a common defense in the Alabama Action, and is
not intended nor should it be construed as a waiver of otherwise applicable privileges. 

  

	 	14.	No Admission of Liability. This Agreement, nor any of the terms and provisions contained herein, nor any of the negotiations or proceedings in connection
therewith, nor any of the documents or statements referred to herein or therein, nor the fact of the Agreement, nor any statements in connection therewith, is or shall be argued to be, used or construed as, offered or received in evidence as, or
otherwise constitute an admission, concession, presumption, proof, evidence, or a finding of any liability, fault, wrongdoing, injury or damages, or of any wrongful conduct, acts or omissions on the part of either party (or either parties’
affiliates or such affiliates’ respective officers, directors, employees, agents, representatives, successors or assignees) in the Minnesota Action or the Alabama Action. 

 

	 	15.	Right to Counsel. The parties hereto understand that they have the right to consult counsel of their own choosing and they have either done so or elected not to
do so of their own choice and free will. 

  

	 	16.	Counterparts. This Agreement may be executed in two or more counterparts, each of which will be considered an original, but all of which together will constitute
one and the same instrument. A facsimile or PDF image of a signature sent by e-mail shall be as binding as an original. 

  

	 	17.	Governing Law and Submission to Jurisdiction. This Agreement will be governed by and construed in accordance with the laws of the State of Delaware, without
giving effect to principles of conflicts of law. Each of the parties submits to the exclusive jurisdiction of any state or federal court sitting in Hennepin or Ramsey County, Minnesota, or Jefferson or Shelby County, Alabama, in any action or
proceeding arising out of or relating to this Agreement, except that any dispute regarding Future Fees under Paragraph 2(b) of this Agreement shall be resolved solely through the binding process set forth in Paragraph 2(b). 

  
 6 

	 	18.	Attorney’s Fees. In the event that suit shall be brought by either party relating to any dispute or controversy arising from this Agreement (including any
dispute regarding Future Fees under Paragraph 2(b) of this Agreement and any binding determination as a result of such a dispute), the prevailing party shall be entitled to recover its reasonable attorney fees, costs, and expenses from the other
party. 

  

	 	19.	Headings. The captions, headings and subheadings used in this Agreement are solely for convenience of reference and shall not constitute a part of this Agreement
or affect in any way the meaning, interpretation, construction or effect of any provision of this Agreement. 

  

 

							
		 		 	SURMODICS, INC.
				
	Dated: July 30, 2013	 		 	By	 	 /s/ Bryan K. Phillips

		 		 	Bryan Phillips
		 		 	Its SVP, Legal and Human Resources, General Counsel & Secretary
			
		 		 	SOUTHERN RESEARCH INSTITUTE
				
	Dated: July 30, 2013	 		 	By	 	 /s/ Nancy M. Gray

		 		 	Nancy M. Gray
		 		 	Its Vice President, Corporate Development

  
 7EX-10.1

 Exhibit 10.1 
 EDGEWATER TECHNOLOGY, INC. 
 STOCK PURCHASE AGREEMENT 

(NON-EMPLOYEE DIRECTOR) 
 THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of the      day of
            ,         , by and between EDGEWATER TECHNOLOGY, INC., a Delaware corporation (the
“Company”), and                     (“Grantee”), a non-employee director of the Company. 

RECITALS 

WHEREAS, in exchange for Grantee’s services, the Company will issue stock of the Company to
Grantee as herein described, on the terms, provisions and conditions hereinafter set forth; 

WHEREAS, the issuance of common stock hereby is being made pursuant to the terms, provisions and
conditions of the Company’s 2012 Omnibus Incentive Plan, as amended (the “Plan”), and is subject to the Plan; and 
 WHEREAS, capitalized terms not otherwise defined in this Agreement, shall have the meanings ascribed thereto in the Plan. 

AGREEMENT 

NOW, THEREFORE, IT IS AGREED between the
parties as follows: 
 1. AWARD OF STOCK. The Company hereby agrees to award
Grantee an aggregate of shares of the Common Stock of the Company (the “Stock”) for a price of $.01 per share in exchange for Grantee’s provision of director services to the Company. Delivery of the Stock shall occur at
the offices of the Company immediately following the execution of this Agreement, or at such other time and place as the parties may mutually agree. 
 2. REDEMPTION OPTION. 
 (a) In the
event Grantee’s director relationship with the Company terminates, then the Company shall have an irrevocable option (the “Redemption Option”), for a period of ninety (90) days after said termination, or such longer
period as may be agreed to by the Company and Grantee, to redeem from Grantee or Grantee’s personal representative, as the case may be, at a cost of $.01 per share to the Company, up to but not exceeding the number of shares of the Stock that
have not vested in accordance with the provisions of Sections 2(b) below as of such termination date; provided, however, that if Grantee makes or has made an 83 (b) Election (as defined below) and if Grantee’s director
relationship with the Company is terminated due to death or Disability (as defined in the Plan), then the Company shall comply with the covenant in the final sentence of Section 11, notwithstanding its exercise of the Redemption Option for
unvested shares of the Stock, if any. 
 (b) The Stock shall
                     until all the shares have vested or have ceased vesting upon the termination of Grantee’s director relationship with the
Company. No further vesting shall occur upon the termination of Grantee’s director relationship with the Company. 

 3. EXERCISE OF REDEMPTION
OPTION. The Redemption Option shall be exercised by written notice signed by an officer of the Company or by any assignee or assignees of the Company and delivered or mailed as provided in Section 14(a). Such notice shall
identify the number of shares of the Stock to be redeemed and shall notify Grantee of the time, place and date for settlement of such redemption, which shall be scheduled by the Company within the term of the Redemption Option set forth in
Section 2(a) above. Upon delivery of such notice, the Company shall become the legal and beneficial owner of the Stock being redeemed and all rights and interest therein or related thereto, and the Company shall have the right to transfer to
its own name the Stock being redeemed by the Company, without further action by Grantee. 
 4. ADJUSTMENTS
TO THE STOCK. If, from time to time, during the term of the Redemption Option there is any change affecting the Company’s outstanding Common Stock as a class that is effected without the receipt
of consideration by the Company (through merger, consolidation, reorganization, reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, change in corporate structure or other
transaction not involving the receipt of consideration by the Company), then any and all new, substituted or additional securities or other property to which Grantee is entitled by reason of Grantee’s ownership of Stock shall be immediately
subject to the Redemption Option and be included in the word “Stock” for all purposes of the Redemption Option with the same force and effect as the shares of the Stock presently subject to the Redemption Option, but only to
the extent the Stock is, at the time, covered by such Redemption Option. 
 5. TERMINATION OF
THE REDEMPTION OPTION. Sections 2, 3, and 4 of this Agreement shall terminate upon the exercise in full or expiration of the Redemption Option, whichever occurs first. 

6. ESCROW OF UNVESTED STOCK. As security for Grantee’s faithful
performance of the terms of this Agreement and to insure the availability for delivery of the Stock to the Company upon exercise of the Redemption Option herein provided for, Grantee agrees, at the delivery of the shares hereunder, to deliver to and
deposit with the Corporate Secretary of Company or the Secretary’s designee (the “Escrow Agent”), as the Escrow Agent in this transaction, four (4) stock assignments duly endorsed (with date and number of shares
blank) in the form attached hereto as Exhibit A, together with a certificate or certificates evidencing all of the Stock subject to the Redemption Option; said documents are to be held by the Escrow Agent and delivered by said Escrow Agent
pursuant to the Joint Escrow Instructions of the Company and Grantee set forth in Exhibit B attached hereto and incorporated by this reference, which instructions shall also be delivered to the Escrow Agent at the time of delivery hereunder.

 7. RIGHTS OF GRANTEE. Subject to the provisions of Sections 6, 8 and 12
herein, Grantee shall exercise all rights and privileges of a stockholder of the Company with respect to the Stock deposited in escrow. Grantee shall be deemed to be the holder for purposes of receiving any dividends that may be paid with respect to
such shares of the Stock and for the purpose of exercising any voting rights relating to such shares of the Stock, even if some or all of such shares of the Stock have not yet vested and been released from the Redemption Option. 

  
 2 

 8. LIMITATIONS ON TRANSFER. In addition
to any other limitation on transfer created by applicable securities laws, Grantee shall not assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Stock while the Stock is subject to the Redemption Option. After any of
the shares of the Stock have been released from the Redemption Option, Grantee shall not assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Stock, except in compliance with the applicable securities laws. Any attempted
transfer in violation of this provision shall be null and void, and the Stock shall be forfeited if so determined by the Company. 
 9. RESTRICTIVE LEGENDS. All certificates representing the Stock shall have endorsed thereon legends in substantially the following forms (in addition to any other
legend which may be required by other agreements between the parties hereto): 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
AN OPTION SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. ANY TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES
SUBJECT TO SUCH OPTION IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.” 
 10.
INVESTMENT REPRESENTATIONS. In connection with the award of the Stock, Grantee represents to the Company the following: 
 (a) Grantee is aware of the business affairs and financial condition of the Company, and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to
acquire the Stock. Grantee is acquiring the Stock for investment for Grantee’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities
Act of 1933, as amended (the “Act”). 
 (b) Grantee is familiar with the provisions of Rules 144
and 701, under the Act, as in effect from time to time, which, in substance, permit limited public resale of “restricted securities” and/or “control securities” acquired, directly or indirectly, from
the issuer thereof (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions. 
 (c) Grantee further understands that at the time Grantee wishes to sell the Stock there may be no public market upon which to make such a sale, and that, even if such a public market then exists,
the Company may not be satisfying the current public information requirements of Rule 144 or 701, and that, in such event, Grantee may be precluded from selling the Stock under Rule 144 or 701 even if the minimum holding period requirement had been
satisfied. 
 11. SECTION 83(b) ELECTION. To the extent Grantee is subject to United
States tax laws, Grantee understands that Section 83(a) of the Internal Revenue Code of 1986, as amended (the “Code”), taxes as ordinary income the difference between the amount paid for the Stock and

  
 3 

 
the fair market value of the Stock as of the date any restrictions on the Stock lapse. In this context, “restriction” includes the right of Company to buy back the Stock
pursuant to the Redemption Option set forth in Section 2(a) above. Grantee understands that, if applicable, Grantee may elect to be taxed at the time the Stock is purchased, rather than when and as the Redemption Option expires, by filing an
election under Section 83(b) (an or the “83(b) Election”) of the Code with the Internal Revenue Service within thirty (30) days from the date of purchase. Even if the fair market value of the Stock at the time
of the execution of this Agreement equals the amount paid for the Stock, the 83(b) Election must be made to avoid income under Section 83(a) in the future. Grantee understands that failure to file such an 83(b) Election in a timely
manner may result in adverse tax consequences for Grantee under United States tax law if those laws are applicable. Grantee further understands that an additional copy of such 83(b) Election is required to be filed with his or her federal
income tax return for the calendar year in which the date of this Agreement falls. Grantee acknowledges that the foregoing is only a summary of the effect of United States federal income taxation with respect to purchase of the Stock hereunder, and
does not purport to be complete. Grantee further acknowledges that the Company has directed Grantee to seek independent advice regarding the applicable provisions of the Code, the income tax laws of any municipality, state or foreign country in
which Grantee may reside, and the tax consequences of Grantee’s death. Grantee assumes all responsibility for filing an 83(b) Election and paying all taxes resulting from such election or the lapse of the restrictions on the Stock. If Grantee
makes or has made an 83 (b) Election with respect to the Stock and if Grantee’s director relationship with the Company is terminated due to death or Disability, then as to unvested shares of the Stock, if any, that are repurchased by the
Company pursuant to the Redemption Option in accordance with Section 2 (a), the Company agrees to pay Grantee or Grantee’s estate, as applicable, the amount of federal and state income taxes paid by Grantee pursuant to an 83
(b) Election for such unvested shares of the Stock that are repurchased by the Company pursuant to the Redemption Option in accordance with Section 2 (a). 
 12. REFUSAL TO TRANSFER. The Company shall not be required: (a) to transfer on its books or authorize its transfer agent to transfer on its book
and records any shares of Stock of Company which shall have been transferred in violation of any of the provisions set forth in this Agreement; or (b) to treat nor shall its transfer agent be required to treat, as owner of such shares or to
accord the right to vote as such owner or to pay dividends to any transferee to whom such shares shall have been so transferred. 
 13. CHANGE IN CONTROL TRANSACTIONS. In the event of a Corporate Transaction (as defined in the Plan), the Redemption Option may be
assigned by the Company to the successor of the Company (or such successor’s parent company), if any, in connection with such event. To the extent the Redemption Option remains in effect following such event, it shall apply to the new capital
stock or other property received in exchange for the Stock in consummation of the Corporate Transaction, but only to the extent the Stock was at the time covered by such right. Appropriate adjustments shall be made to the price per share payable
upon exercise of the Redemption Option to reflect the Corporate Transaction upon the Company’s capital structure; provided, however, that the aggregate price per share payable upon exercise of the Redemption Option shall remain
the same. 

  
 4 

 14. MISCELLANEOUS. 

(a) Notices. Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given
upon personal delivery or sent by telegram or fax or upon deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to the other party hereto at his address hereinafter shown below its
signature or at such other address as such party may designate by ten (10) days’ advance written notice to the other party hereto. 
 (b) Successors and Assigns. This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer herein set forth, be binding
upon Grantee, Grantee’s successors, and assigns. 
 (c) Governing Law; Venue. This Agreement shall be
governed by and construed in accordance with the laws of the State of Delaware. The parties agree that any action brought by either party to interpret or enforce any provision of this Agreement shall be brought in, and each party agrees to, and does
hereby, submit to the jurisdiction and venue of, the appropriate state or federal court for the district encompassing the Company’s principal place of business. 
 (d) Further Execution. The parties agree to take all such further action(s) as may reasonably be necessary to carry out and consummate this Agreement as soon as practicable, and to take
whatever steps may be necessary to obtain any governmental approval in connection with or otherwise qualify the issuance of the securities that are the subject of this Agreement. 

(e) Entire Agreement; Amendment. This Agreement constitutes the entire agreement between the parties with respect to the
subject matter hereof and supersedes and merges all prior agreements or understandings, whether written or oral. This Agreement may not be amended, modified or revoked, in whole or in part, except by an agreement in writing signed by each of the
parties hereto. 
 (f) Severability. If one or more provisions of this Agreement are held to be unenforceable
under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then: (i) such provision shall be excluded from
this Agreement; (ii) the balance of this Agreement shall be interpreted as if such provision were so excluded; and (iii) the balance of this Agreement shall be enforceable in accordance with its terms. 

(g) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and
all of which together shall constitute one instrument. 

  
 5 

 IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the day and year first above written. 
  

			
	EDGEWATER TECHNOLOGY, INC.
		
	By:	 	  

		
	Title:	 	

  

			
	GRANTEE:
	
	  

		
	Address:	 	  

		 	  

 Exhibit A – Stock Assignment Separate from Certificate 

Exhibit B – Joint Escrow Instructions 

  
 6 

 EXHIBIT A 
 STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE 
 FOR
VALUE RECEIVED,                      hereby sells, assigns and transfers unto EDGEWATER
TECHNOLOGY, INC., a Delaware corporation (the “Company”), pursuant to the Redemption Option under that certain Stock Purchase Agreement, dated
            ,         , by and between the undersigned and the Company (the “Agreement”),
                     shares of common stock of the Company standing in the undersigned’s name on the books of the Company represented by
Certificate(s) No.          and does hereby irrevocably constitute and appoint the Company’s Secretary to transfer said stock on the books of the Company with full power of substitution in the premises
(this “Assignment”). This Assignment may be used only in accordance with and subject to the terms, provisions and conditions of the Agreement, in connection with the redemption of shares of common stock of the Company issued to the
undersigned pursuant to the Agreement, and only to the extent that such shares remain subject to the Company’s Redemption Option under the Agreement. 
  

			
	Dated:	 	  

  

	
	  

	(Signature)
	
	  

  
 A-1

 EXHIBIT B 
 JOINT ESCROW INSTRUCTIONS 
 Corporate Secretary 

Edgewater Technology, Inc. 
 200 Harvard Mill
Square, Suite 210 
 Wakefield, MA 01880 
 To whom it may concern: 
 As Escrow Agent for both Edgewater Technology,
Inc., a Delaware corporation (the “Company”), and                     
(“Grantee”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Stock Purchase Agreement dated as of
            ,          (the “Agreement”), to which a copy of these Joint Escrow Instructions is attached
as Exhibit B, in accordance with the following instructions: 
 1. In the event the Company or an assignee shall elect to exercise
the Redemption Option set forth in the Agreement, the Company or its assignee will give to Grantee and you a written notice specifying the number of shares of Stock to be redeemed, and the time for a closing thereunder at the principal office of the
Company. Grantee and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. 
 2. At the closing, you are directed: (a) to date the Stock assignments necessary for the transfer in question; (b) to fill in the number of shares being transferred; and (c) to
deliver the same, together with the certificate evidencing the shares of Stock to be transferred, to the Company for the number of shares of stock being redeemed pursuant to the exercise of the Redemption Option. 

3. Grantee irrevocably authorizes the Company to deposit with you any certificates evidencing shares of Stock to be held by you hereunder and any
additions and substitutions to said shares as specified in the Agreement. Grantee does hereby irrevocably constitute and appoint you as his attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all
documents necessary or appropriate to make such securities negotiable and complete any transaction herein contemplated, including but not limited to any appropriate filing with state or government officials or bank officials. Subject to the
provisions of this paragraph 3, Grantee shall exercise all rights and privileges of a stockholder of the Company while the stock is held by you. 
 4. This escrow shall terminate upon the exercise in full or expiration of the Redemption Option, whichever occurs first. 
 5. If at the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to Grantee, you shall deliver all of the same to Grantee
and shall be discharged of all further obligations hereunder; provided, however, that if at 

  
 B-1

 
the time of termination of this escrow you are advised by the Company that any property subject to this escrow is the subject of a pledge or other security agreement, you shall deliver all such
property to the pledgeholder or other person designated by the Company. 
 6. Except as otherwise provided in these Joint Escrow
Instructions, your duties hereunder may be altered, amended, modified or revoked only in writing, signed by all of the parties hereto. 

7. You shall be obligated only for the performance of such duties as are specifically set forth herein and may rely and shall be protected in
relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as
Escrow Agent or as attorney-in-fact for Grantee while acting in good faith and in the exercise of your own good judgment, and any act done or omitted by you pursuant to the advice of your own attorneys shall be conclusive evidence of such good
faith. 
 8. You are hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other
person or entity, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree of any
court, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside,
vacated or found to have been entered without jurisdiction. 
 9. You shall not be liable in any respect on account of the identity,
authorities or rights of the parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. 
 10. You shall not be liable for the loss of any rights under any statute of limitations with respect to these Joint Escrow Instructions or any documents deposited with you. 

11. Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to be the Corporate Secretary of the Company or if you
shall resign by written notice to each party. In the event of any such termination, the Company shall appoint any officer or assistant officer of the Company as successor Escrow Agent, and Grantee hereby confirms the appointment of such successor as
his attorney-in-fact and agent to the full extent of your appointment. 
 12. If you reasonably require other or further instruments in
connection with these Joint Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments. 
 13. It is understood and agreed that should any dispute arise with respect to the delivery and/or ownership or right of possession of the securities held by you hereunder, you are authorized and
directed to retain in your possession without liability to anyone all or any part of said securities until such dispute shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a
court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings. 

  
 B-2

 14. Any notice required or permitted hereunder shall be given in writing and shall be deemed
effectively given upon personal delivery, including delivery by express courier, or five (5) days after deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other
parties entitled to such notice at the following addresses, or at such other addresses as a party may designate by ten days’ advance written notice to each of the other parties hereto. 

 

					
	Company:	  	Edgewater Technology, Inc.	  	
		  	200 Harvard Mill Square, Suite 210	  	
		  	Wakefield, MA 01880	  	
			
	Grantee:	  		  	
		  	  
	  	
		  	  
	  	
			
	Escrow Agent:	  	Corporate Secretary	  	
		  	200 Harvard Mill Square, Suite 210	  	
		  	Wakefield, MA 01880	  	

 15. By signing these Joint Escrow Instructions, you become a party hereto only for the purpose of said Joint
Escrow Instructions; you do not become a party to the Agreement. 
 16. You shall be entitled to employ such legal counsel and other
experts as you may deem necessary properly to advise you in connection with your obligations hereunder. You may rely upon the advice of such counsel, and you may pay such counsel reasonable compensation therefor. The Company shall be responsible for
all fees generated by such legal counsel in connection with your obligations hereunder. 
 17. This instrument shall be binding upon and
inure to the benefit of the parties hereto and their respective successors and permitted assigns. It is understood and agreed that references to “you” and “your” herein refer to the original Escrow
Agent. It is understood and agreed that the Company may at any time or from time to time assign its rights under the Agreement and these Joint Escrow Instructions. 
 18. This Agreement shall be governed by and interpreted and determined in accordance with the laws of the State of Delaware as such laws are applied by Delaware courts to contracts made and to be
performed entirely in Delaware by residents of that state. 

  
 B-3

 
			
	Very truly yours,
	
	EDGEWATER TECHNOLOGY, INC.
		
	By:	 	  

	Title:	 	

  

	
	GRANTEE:
	
	  

  

	
	ESCROW AGENT:
	
	  

 [SIGNATURE PAGE TO JOINT ESCROW INSTRUCTIONS] 

  
 B-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]